Pharmacoeconomic impact of non-compliance with statins

PharmacoEconomics

Volumn 23, Issue 1, 2005, Pages 13-25

  Peterson, Andrew M ^a   McGhan, William F ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK; SIDE EFFECT;

EID: 13244279642     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523010-00002     Document Type: Review

References (42)

1. National Center for Chronic Disease Prevention and Health Promotion. Preventing heart disease and stroke [online]. Available from URL: http://www.cdc.gov/nccdphp/bb_heartdisease/index.htm [Accessed 2004 May 1]
2. Task Force for Compliance. Noncompliance with medication regimens: an economic tragedy: emerging issues in pharmaceutical cost containing. Washington, DC: National Pharmaceutical Council, 1994: 1-32
3. McGhan WF, Peterson AM. Pharmacoeconomic impact of non-compliance. US Pharmacist Impact 2001, 3-13
4. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med 1986; 80 (2A): 33-9
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615-22
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333 (20): 1301-7
7. Scandinavia Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19): 1349-57
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335 (14): 1001-9
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
11. Top 200 brand-name drugs by units in 2002. Drug Topics 2003; 60-2
12. Meichenbaum D, Turk DC. Facilitating treatment adherence: a practitioner's guidebook. New York: Plenum, 1987
13. Flanagan A, Gartenmann T, Lovich D, et al. The hidden epidemic: finding a cure for unfilled prescriptions and missed doses [online]. Available from URL: http://www.bcg.com/publications/files/TheHiddenEpidemic_Rpt_HCDec03.pdf [Accessed 2003 Dec 18]
14. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24 (2): 302-16
15. Beardon PHG, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 846-8
16. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001; 41: 192-9
17. Secnik K, Pathak DS, Cohen JM. Postcard and telephone reminders for unclaimed prescriptions: a comparative evaluation using survival analysis. J Am Pharm Assoc (Wash) 2000; 40: 243-51
18. McCaffrey DJ, Smith MC, Banahan BF, et al. The financial implications of initial noncompliance: an investigation of unclaimed prescriptions in community pharmacies. J Res Pharmaceut Econ 1995; 6: 39-64
19. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30
20. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-8
21. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002; 88: 229-33
22. Hughes DA, Bagust A, Haycox A, et al. Accounting for non-compliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19: 1185-97
23. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 1125-31
24. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486-97
25. Mansur AP, Mattar APL, Tsubo CE, et al. Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia. Arq Bras Cardiol 2001; 76: 115-8
26. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458-62
27. Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J Manag Care Pharm 2003; 9: 544-51
28. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999 Mar; 15 (3): 217-28
29. Peterson AM, Sanoski C, McGhan WF. Total direct medical and drug costs of non-adherence to statin therapy within the first year of treatment: International Society for Pharmacoeconomics and Outcomes Research [abstract]. Value Health 2002; 3: 167
30. Peterson AM, McGhan WF. A decision analysis model for enhancing medication adherence in patients taking statins. Value Health 2001; 4: 500
31. Hamilton VH, Racicot FE, Zowall H, et al. The cost effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA 1995; 273: 1032-8
32. Martens LL, Guibert. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16: 1052-62
33. Berto P, Mubro V, Gaddi A, et al. Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy. Clin Drug Invest 2000; 20: 109-21
34. Ashraf T, Hay JW, Pitt B, et al. Cost effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409-14
35. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000; 132:780-7
36. Huse DM, Mason RW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82: 1357-63
37. Johannsenn M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary health disease: Scandinavian Simvastatin Survival Study Group (4S). N Engl J Med 1997; 336: 332-6
38. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132: 769-79
39. Riviere M, Wang S, Lecrlerc, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997; 156: 991-7
40. Metz CA, Lucas KH. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother 2001; 35 (4): 496-500
41. Iliff D. Weekly versus daily dosing of atorvastatin. J Fam Pract 2002; 51: 365-6
42. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002; 144: 674-7